Plasma Protease C1-inhibitor Treatment Market Company Analysis, Forecast, Share, Growth, Size and Trends 2018 - 2027

Plasma Protease C1-inhibitor Treatment

The Plasma Protease C1-inhibitor Treatment Market is predicted to rise due to biopharmaceutical firms' increased attention on developing effective plasma protease C1-inhibitor treatment drugs/therapy for a variety of health disorders such as HAE, diabetic macular edema (DME), and others. Several kallikrein inhibitors are now in the preclinical and clinical stages of development. For example, Oxurion announced promising topline findings from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema in September 2019. (DME).

For example, Oxurion announced promising topline findings from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edoema, in September 2019. (DME). Additionally, KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced the results of Phase 2 clinical trial evaluating the use of KVD001 in diabetic macular edoema patients in December 2019. (DME).

In addition, the use of inorganic growth techniques such as partnerships and collaborations to develop innovative protease C1-inhibitor therapy is helping to drive the global Plasma Protease C1-inhibitor Treatment Market. For example, in October 2017, KalVista Pharmaceuticals, Inc. signed a partnership agreement for KVD001 with Merck, which is known as MSD outside the United States and Canada (investigational plasma kallikrein inhibitors). The company is actively developing an investigational intravitreal (IVT) injection candidate for the treatment of diabetic macular edoema (DME).

However, the infrequent occurrence of HAE makes accurate diagnosis difficult, and the use of alternative medicines to control the disease are projected to limit the plasma protease c1-inhibitor therapy market's growth over the projection period. Due to growing approvals of novel therapeutics by regulatory agencies such as the US Food and Drug Administration, the Plasma Protease C1-inhibitor Treatment Market in North America is likely to develop significantly over the forecast period. Ruconest, a recombinant C1-esterase inhibitor developed by Pharming Healthcare, was licensed by the US FDA in 2014 for the treatment of acute attacks in adult and adolescent patients with HAE.